Finally, the firm notes that in recent months certain institutions have been disseminating misleading information in order to profiteer from short selling. The firm rejects such malicious short selling activities. We will stay in communication with relevant regulatory authorities and reserve our right to hold those disseminating false information accountable in accordance with the law.
EV stocks fell in morning trading,with Lucid sliding over 3%,TuSimple and Xpeng sliding over 2%<blockquote>电动汽车股早盘下跌,Lucid跌超3%,图森未来和小鹏汽车跌超2%</blockquote>
$Tiger Brokers(TIGR)$200k unit can caused the share price drop to below rm5. Something is unbelievable. Sentiment is so bad now. No one care Tiger whether with future or not. All concern current regulations matters in US and China. lol
(Reuters) - Laboratory analysis of the antibody-based COVID-19 therapy GlaxoSmithKline (GSK) is developing with U.S. partner Vir has indicated the drug is effective against the new Omicron variant, the British drugmaker said on Thursday.A GSK statement said that lab tests and a study on hamsters have demonstrated the sotrovimab antibody cocktail to work against viruses that were bio-engineered to carry a number of hallmark mutations of the Omicron variant.